February 09, 2009
1 min read
Save

Once-monthly ibandronate increased total hip BMD at one year in postmenopausal women

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Postmenopausal women who received one year of monthly ibandronate treatment experienced increases in total quantitative CT bone mineral density, as well as integral and trabecular bone at multiple sites at the hip and spine, according to results of a double blind, placebo-controlled trial.

The researchers randomly assigned postmenopausal women aged 55 to 80 years to oral ibandronate (Boniva, Roche) 150 mg per month (n=47) or placebo (n=46). Researchers calculated strength using quantitative CT with finite elementary analysis and DXA with hip structural analysis.

At baseline, all women had BMD T-scores ranging from ≤–2.0 to ≥–5. One year of ibandronate treatment improved total hip and spine quantitative CT BMD (the primary endpoint) and DXA areal BMD more than placebo (2.2%; P=.005 vs. 2%; P=.003).

Ibandronate improved multiple finite element analysis indices of hip and spine strength, including hip strength:density ratio (4.1%; P<.001) and femoral (5.9%; P<.001), peripheral (2.5%; P=.011) and trabecular strength (3.5%; P=.003) compared with placebo.

Bisphosphonate treatment was associated with improvements in vertebral (7.1%; P<.001), peripheral (7.8%; P<.001) and trabecular strength (5.6%; P=.023) and anteroposterior bending stiffness (6.3%; P<.001). Women assigned to ibandronate experienced effects on hip structural analysis indices that were specific to the femoral narrow neck cross-sectional area (3.6%; P=.003) and increases in moment of inertia (4%; P=.052) and outer diameter (2.2%; P=.049).

J Clin Endocrinol Metab. 2009;94:171-180.